Navigation Links
GTx Announces Ostarine Improved Insulin Resistance among Elderly,Patients in a Recently Completed Phase II Clinical Trial

, without limitation, the risks that (i) GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not able to obtain required regulatory approvals to commercialize its product candidates; (iii) GTx's clinical trials may not be initiated and/or completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's annual report on form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 9, 2007, contains under the heading "Risk Factors," a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact

GTx, Inc.
McDavid Stilwell, 901-523-9700
Director, Corporate Communications & Financial Analysis


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/23/2015)... new analysis of Centers for Medicare and Medicaid Services, ... 81 percent of seniors chose lower-cost preferred pharmacy plans ... pharmacies. The findings were released by Drug Channels ... foundation of Medicare Part D," said Pharmaceutical Care Management ...
(Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Oct. 7 DiFUSION Technologies is a medical ... of its proprietary CleanFUZE™ antimicrobial technology for orthopedic ... Interbody products for spinal surgery. "Post-operative ... the further proliferation of drug resistant bacteria, preventing ...
... Community Pharmacists Association (NCPA) has announced its current ... and Trade Exposition scheduled for October 23-27, 2010 ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100106/DC33253LOGO ) (Logo:   ... Exposition is the most powerful and productive trade ...
Cached Medicine Technology:DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial 2DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial 3NCPA Announces Exhibit Hall Activities for 2010 NCPA Annual Convention and Trade Exposition 2
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that focuses ... representation client review requests for slip and fall accidents in ... the number of slip and fall related accidents that happen ... that said, a large number of injury victims are requesting ... Hastings and Hastings is a personal injury firm in Arizona ...
(Date:1/22/2015)... 23, 2015 LunaDress, with its top dressmaking ... industry. Now, the business is showing its latest designs of ... , According to the company’s CEO, all the fresh new ... with big discounts, up to 80% off. All the clothes ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... treatment plan used to prevent potentially dangerous blood clots ... immobilized by acute medical illness, doctors have found in ... or older, and patients strictly confined to 24-hour bed ... thinner significantly reduced the chances of blood clots while ...
... Gardner HealthDay Reporter , TUESDAY, July 6 (HealthDay ... blood pressure levels in type 2 diabetics who also have ... and coronary artery disease did not have fewer strokes or ... their blood pressure was maintained under 130 mm Hg, compared ...
... in French . Montreal, July 6, ... Research in Immunology and Cancer (IRIC) of the University of ... (hematopoietic) stem cells. The study led by IRIC Chief Executive ... control the production of hematopoietic stem cells. Published in the ...
... than one species of bacteria could be more persistent ... the other, encouraging it to bolster its defenses. ... curing these infections. Researchers from Wake Forest University ... mBio , the online open-access journal of the American ...
... ... expansion into Brooklyn, New York through a merger with Otolaryngology Associates. , ... Tarrytown, NY (Vocus) July 6, 2010 -- ... into Brooklyn, New York through a merger with Otolaryngology Associates. This will result in a ...
... Los Angeles and childhood cancer patients will together take part in ... their hands in fingerpaint and apply colorful handprints to a white ... handprints from all over the country, is the symbol of Hyundai ... cure rate means that in the general population of young adults, ...
Cached Medicine News:Health News:Extended use of anti-clotting drug helps some bedridden patients 2Health News:Extended use of anti-clotting drug helps some bedridden patients 3Health News:Tight Blood Pressure Control Doesn't Help All Diabetics: Study 2Health News:Researchers identify factors behind blood-making stem cells 2Health News:Bacterial communication encourages chronic, resistant ear infections 2Health News:ENT and Allergy Associates Adds Two Offices in Brooklyn, NY -- Practice Grows to 110 Physicians, 2Health News:ENT and Allergy Associates Adds Two Offices in Brooklyn, NY -- Practice Grows to 110 Physicians, 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: